Abstract：Objective To compare the efficacy of three treatments on mild to moderate infantile wheeze.Methods Sixty children with mild to moderate wheezing were enrolled in the pediatric outpatients of the First Clinical College of Harbin Medical University, and were randomly allocated to the three treatment groups:(A) 2 times daily Budesonide Suspension for inhalation 2 ml (1 mg) + Compound Ipratropium Bromide Solution for inhalation (1 ml); (B) 2 times daily Budesonide Suspension for inhalation 2 ml (1 mg) + Compound Ipratropium Bromide Solution for inhalation 1 ml + Montelukast Sodium Chewable Tablets (4 mg/d); and (C) Montelukast Sodium Chewable Tablets (4 mg/d) + Tulobuterol Patch (0.5 mg/d). We evaluated the clinical symptoms and signs prior to the initiation of and 3, 7, and 10 days after the treatments. We compared the effect of the three treatments on the improvement of clinical symptoms and signs, and the prevalence of adverse events among the three groups.Results Clinical symptoms and signs for participants in all the three groups were significantly improved at 3, 7 and 10 days after the treatments, but the effects did not differ between groups. There was no difference in the mean days of recovery among groups (8.68±1.56, 8.21±1.03, and 8.54±1.03 for group A, B, and C, respectively).Conclusion While the combination of Montelukast Sodium Chewable Tablets and Tulobuterol Patch is more convenient and practical and often has good compliance in clinical settings, there was no difference regarding the effects of the three treatments for mild to moderate infantile wheeze.
